Pfizer and Astellas’ Padcev, Plus Keytruda, Delivers ‘Breakthrough’ Win in New Bladder Cancer Use

Pfizer, Astellas, and Merck’s Padcev-Keytruda combo achieved a major phase 3 win in muscle-invasive bladder cancer patients ineligible for cisplatin. In the trial, treatment before and after surgery significantly improved event-free survival, overall survival, and complete response rates versus surgery alone. These results signal a potential new standard of care, offering a breakthrough option for patients with limited treatment choices.